-+ 0.00%
-+ 0.00%
-+ 0.00%

60 Degrees Pharmaceuticals Faces Nasdaq Delisting Over Minimum Bid Price Violation

PUBT·11/20/2026 21:59:05
60 Degrees Pharmaceuticals Faces Nasdaq Delisting Over Minimum Bid Price Violation
  • 60 Degrees Pharmaceuticals received a Nasdaq delisting notice on November 19, 2026, for failing the exchange's minimum bid price requirement.
  • Its listed securities closed below $1.00 for 30 consecutive business days, from October 8 through November 18, 2026.
  • Reverse splits of 1-for-5 on February 24, 2025, and 1-for-4 on January 20, 2026, eliminated eligibility for a compliance period.
  • The company requested a hearing and paid the $20,000 fee, staying the December 1, 2026, trading suspension pending the panel's decision.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-122759), on November 20, 2026, and is solely responsible for the information contained therein.